Results 51 to 60 of about 540,096 (367)

Thromboembolic Events Burden in Patients With Solid Tumors and Their Predisposing Factors

, 2022
INTRODUCTION: The relationship between cancers and thromboembolic events is well established. In our study, we aim to determine the burden of thromboembolic events in patients with solid tumors and identify the risk factors related to their development ...
Alkhaldi, Turkiah, Aseafan, Mohamed, Aljumaa, Jihad, Alghabban, Abdulrahman, Almuhisen, Sara, Owaidah, Tarek, Alzahrani, Hazzaa, Eldali, Abdelmoneim, Melaibari, Maryam, Maraiki, Fatma, Bazarbashi, Shouki, Alharbi, Samar   +11 more
core   +1 more source

EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth

Journal of Hematology & Oncology, 2017
Background Activated protein C/endothelial protein C receptor (APC/EPCR) axis is physiologically involved in anticoagulant and cytoprotective activities in endothelial cells.
Naiara Perurena, Carolina Zandueta, Susana Martínez-Canarias, Haritz Moreno, Silvestre Vicent, Ana S. Almeida, Elisabet Guruceaga, Roger R. Gomis, Marta Santisteban, Mikala Egeblad, José Hermida, Fernando Lecanda   +11 more
doaj   +1 more source

Pre‐analytical optimization of cell‐free DNA and extracellular vesicle‐derived DNA for mutation detection in liquid biopsies

Molecular Oncology, EarlyView.
Pre‐analytical handling critically determines liquid biopsy performance. This study defines practical best‐practice conditions for cell‐free DNA (cfDNA) and extracellular vesicle–derived DNA (evDNA), showing how processing time, storage conditions, tube type, and plasma input volume affect DNA integrity and mutation detection.
Jonas Dohmen, Lucrezia De Santis, Bret M. Stephens, Vincent Bernard, Jörg C. Kalff, Lara Braun, Phillipp Leyendecker, Johannes Röttgen, Daniel Weissinger, Anirban Maitra, Paola A. Guerrero, Alexander Semaan   +11 more
wiley   +1 more source

Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors

, 2018
Background: Currently, molecularly targeted drugs are part of the therapeutic arsenal for the treatment of many neoplasms and are responsible for improvements in the quality of life and survival of patients.
Auro Del Giglio, Fabio Iazetti Lopes, Vanessa Salzano, Jose Guzman, Daniel I G Cubero, Jean Schoueri, Beatrice Martinez Zugaib Abdalla, Karine Corcione Turke, Carlos D’Apparecida Santos Machado Filho, Dolores Gonzalez Fabra   +9 more
core   +1 more source

Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma

Journal of Experimental & Clinical Cancer Research
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options and a poor prognosis. The critical role of epigenetic alterations such as changes in DNA methylation, histones modifications, and chromatin ...
Daniel Oyon, Amaya Lopez-Pascual, Borja Castello-Uribe, Iker Uriarte, Giulia Orsi, Sofia Llorente, Jasmin Elurbide, Elena Adan-Villaescusa, Emiliana Valbuena-Goiricelaya, Ainara Irigaray-Miramon, Maria Ujue Latasa, Luz A. Martinez-Perez, Luca Reggiani Bonetti, Felipe Prosper, Mariano Ponz-Sarvise, Silvestre Vicent, Antonio Pineda-Lucena, David Ruiz-Clavijo, Bruno Sangro, Urko Aguirre Larracoechea, Tian V. Tian, Andrea Casadei-Gardini, Irene Amat, Maria Arechederra, Carmen Berasain, Jesus M. Urman, Matias A. Avila, Maite G. Fernandez-Barrena   +27 more
doaj   +1 more source

Solid Tumours [PDF]

, 2018
Solid tumor chapter describes the main indication of stem cell transplanation in the various types of solid tumors.
Ruth Ladenstein, Evgenia Glogova, Francesco Lanza   +2 more
openaire   +1 more source

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source

689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study [PDF]

, 2023
Omkar Marathe, Ying Cheng, Alexander I. Spira, Erika Hamilton, Maria M. Rubinstein, X. Dong, Li Li, Dongqing Lv, Jingyun Shi, Nashat Gabrail, H. Amin, C. Wu, Zhe Zhu, Yue Qiu, Vivian W. Gu, Xueting Qiu, Rui Shi, Li Liu, Ping Miao, Naoto T. Ueno   +19 more
openalex   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

Sweet dreams could be made of this: carbohydrate‐responsive element‐binding protein (ChREBP) as a target for hepatocellular carcinoma therapy

Molecular Oncology
Rewiring of cellular metabolism is now fully recognized as a hallmark of cancer. Tumor cells reprogram metabolic pathways to meet the energetic and macromolecular demands to support unrestricted growth and survival under unfavorable conditions.
Maite G. Fernández‐Barrena, Matías A. Avila   +1 more
doaj   +1 more source